Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Urology
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
1756287209105264v1
1/2/67    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bahnson, R. R
Right arrow Articles by Povoski, S. P
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

PET/CT imaging of clear cell renal cell carcinoma with 124I labeled chimeric antibody

Robert R Bahnson*, Eamonn E Bahnson, Douglas A Murrey, Cathy M Mojzisik, Nathan C Hall, Humberto J Martinez-Suarez, Michael V Knopp, Edward W Martin, and Stephen P Povoski

The Ohio State University

* To whom correspondence should be addressed. E-mail: eamonn.bahnson{at}osumc.edu.


  Abstract

Clear cell renal cell carcinoma (ccRCC) presents problems for urologists in diagnosis, treatment selection, intraoperative surgical margin analysis, and long term monitoring. In this paper we describe the development of a radiolabeled antibody specific to ccRCC (124I-cG250) and its potential to help urologists manage each of these problems. We believe 124I-cG250, in conjunction with perioperative Positron emission tomography/computed tomography imaging and intraoperative handheld gamma probe use, has the potential to diagnose ccRCC, aid in determining a proper course of treatment (operative or otherwise), confirm complete resection of malignant tissue in real time, and monitor patients post-operatively.

First published on May 21, 2009, doi:10.1177/1756287209105264

Therapeutic Advances in Urology 2009;1:67.

A more recent version of this article appeared on June 1, 2009

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?